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Cytochrome P450 (CYP) enzymes are responsible for the metabolism of numerous xenobiotics
and endogenous compounds, including the metabolic activation of most environmental toxic
chemicals and carcinogens. Both metabolic and genetic polymorphisms have been identified for
human CYP enzymes. The association of CYP genetic polymorphism and human cancer risk, and
susceptibility to environmental hazards, have received increasing attention. This article briefly
reviews the approaches and methods currently used in CYP genetic polymorphism studies. In
addition, the current status and perspectives of using CYP genetic polymorphism as a biomarker
of individual susceptibility to cancer and environmental toxicity are discussed. Environ Health
Perspect 105(Suppl 4):759-762 (1997)
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Cytochrome P450s (CYPs) are asuperfamily
ofhemoproteins that catalyze the biotrans-
formation ofvarious xenobiotics and endo-
biotics (1,2). Although there are overlapping
substrate specificities, individual CYP
forms have significant differences in their
substrate preferences. On the basis ofthis
specificity, selective activity assays with dif-
ferent substrates have been used to establish
markers forparticular CYP forms.
It is well established that most environ-
mental toxic chemicals and carcinogens
need to be metabolically activated to exert
their toxic or carcinogenic effects. As a
major enzyme system in xenobiotic metab-
olism, CYPs playacritical role in the meta-
bolic activation of many environmental
chemicals. In some cases, CYP-catalyzed
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metabolism leads to the detoxification of
toxic chemicals.
Of15 human CYP enzymes so far char-
acterized, 8 forms ofCYP (CYPlAI, 1A2,
2A6, 2C9, 2C19, 2D6, 2E1, and 3A4)
have been shown to be polymorphic at the
phenotypic or genotypic level, or both
(3-5). In addition to metabolizing various
drugs, these polymorphic CYP enzymes are
involved in metabolizing a large number of
environmental carcinogens and toxic com-
pounds (1). Because an individual's capa-
bility to metabolize these toxicants can be
altered by carrying the variant alleles,
genetic polymorphisms ofCYP enzymes
have been proposed as a biomarker ofsus-
ceptibility to environmental carcinogenesis
and toxicity. This paper briefly reviews the
methodologies for CYP polymorphism
studies and emphasizes the comparison
between the genotyping and phenotyping
approaches. The use ofgenetic polymor-
phisms ofhuman CYP enzymes as asuscep-
tibility biomarker and the direction of
future researchwill be discussed.
Phenotypic Determination
ofCYP Polymorphisms
It is well known that there are large
interindividual variations in CYP-catalyzed
drug biotransformation (1). The CYP poly-
morphisms wereinitiallyidentified bydeter-
mining the metabolic ratio, i.e., the ratio of
the blood or urinary amount ofthe parent
drug over its metabolite, in individuals to
whom the probe drug was administered.
Metabolic polymorphism is usually
indicated in a population where the fre-
quency distribution of the metabolic ratio
is shown to be bimodal or trimodal. The
bimodal distribution is due to the existence
ofpoor and extensive metabolizers, whereas
the trimodal distribution is caused by the
presence ofadditional intermediate metab-
olizers. Examples for bimodal distribution
include debrisoquine 4-hydroxylation
(catalyzed by CYP2D6) and coumarin
7-hydroxylation (catalyzed by CYP2A6)
(6). The 3-demethylation ofcaffeine is an
activity marker ofCYP1A2, and a trimodal
distribution for caffeine metabolism was
observed in nonsmokers (7).
Besides the metabolism in vivo, the
polymorphisms of CYP enzymes can be
determined at other phenotypic levels.
These include enzyme activity determina-
tions for metabolism in vitro with micro-
somes, CYP enzyme protein levels detected
by immunological methods such as immu-
noblot and immunohistochemical analyses,
and CYP mRNA levels measured by differ-
ent nucleic acid hybridization techniques
(Northern and slot blotting, RNase protec-
tion, and in situ hybridization). In recent
years researchers have developed reverse
transcription coupled with polymerase
chain reaction (RT-PCR) to detect CYP
mRNA in a small amount oftissue sample.
If an appropriate internal standard is
included in the cDNA synthesis reaction,
the RT-PCR can be quantitative in assess-
ing the amount ofCYP mRNA in the sam-
ples. Expression of CYPIAI mRNA in
human lymphocytes and its regulation by
2,3,7,8-tetrachlorodibenzo-p-dioxin have
been successfully determined by this
method (8).
The phenotyping approach, especially
with activity-related assays such as metabo-
lism in vivo and in vitro, directly links the
expression of a given CYP form to the
metabolism ofits probe substrate. However,
a critical issue is the difficulty in finding
the right probe drugs that are specific for
diagnosing a particular CYP form and safe
enough for in vivo metabolism studies.
Another major concern with the pheno-
typing approach is the confounding effects
ofdietary factors or coadministration of
drugs that could affect expression of the
metabolizing CYP enzymes (9). This
could, in turn, alter the metabolism ofthe
probe drug. Induction or suppression of
CYP enzyme activities by xenobiotics,
including dietary compounds, has been
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well documented in animals (9). In
humans, induction of CYP2E1 by alcohol
drinking (10) and ofCYP1A2 by ingestion
of charbroiled meats or cruciferous vegeta-
bles have been observed (11). In addition,
human CYP1A2 is induced by cigarette
smoking (12,13). Finally, the availability
of substantial amounts ofquality-assured
human tissues (except peripheral blood
cells) could be a limiting factor for deter-
mination of CYP enzyme activity in vitro,
as well as for determination ofCYP protein
and mRNA levels.
Genetic Basis of Metabolic
Polymorphisms
The genetic basis ofseveral CYP-involved
metabolic polymorphisms has been eluci-
dated. Mutations in the CYP genes are
believed to be a major mechanism for alter-
ing enzyme expression and/or catalytic
activities. Both point mutations and dele-
tions are observed in the polymorphic CYP
genes. Depending on their locations in the
gene sequence, polymorphic changes could
have either two general effects or none at
all. Mutations in the coding region of a
CYP gene that cause amino acid substitu-
tions could alter the catalytic activity by
causing a direct change in the protein
structure. Mutations in the noncoding
region, on the other side, may alter the
level of mRNA expression by influencing
transcription, mRNA stabilization, or pre-
mRNA splicing. All of the mutations with
functional significance are believed to have
a remarkable impact on an individual's
capability to metabolize certain drugs and
environmental chemicals. However, the
functional significance of a majority ofthe
polymorphic changes in CYP genes so far
identified is still not known.
Once the metabolic polymorphism
involving a particular CYP enzyme is
demonstrated, various molecular biology
approaches and techniques can be used to
look for possible genetic changes. A success-
ful example ofthis approach is the discovery
of CYP2D6 genetic polymorphism by
Gonzales et al. (14). After cDNA cloning
and DNA sequencing, they demonstrated
that a mutant 2D6allele is responsible for
the majority of"poor metabolizers." Further
work established that a mutation at a splic-
ing site caused the production ofdtfective
2D6 mRNA and a total absence of 2D6
protein (15). Prior to labor-intensive DNA
sequencing work, the possible DNA
sequence alterations can now be screened by
single-strand conformation polymorphism
analysis that detects the mutation-caused
mobility shift ofthe DNA fragments on gel
electrophoresis (16) or by other methods
such as denaturing gradient gel elec-
trophoresis (17). For functional analysis,
the catalytic activity ofCYP enzymes can be
studied by expressing different variant CYP
proteins with various cDNA expression
systems if the polymorphic changes are
localized in the coding region. Ifthe poly-
morphic loci are in the noncoding region,
their effects on the transcriptional regulation
can be studied by linking the mutated
sequence with a reporter gene.
Genotyping Approach
As long as the polymorphic sites of a CYP
gene are clearly identified, it is simple to
determine an individual's genotype by cur-
rent molecular biology techniques. If a
polymorphic site in a CYP gene changes
the recognition sequence of a restriction
enzyme, or if the genetic polymorphism
involves a large deletion, the genetic poly-
morphism can be identified by restriction
fragment length polymorphism (RFLP)
analysis, in which DNA is subjected to
Southern blotting after digestion with appro-
priate restriction enzymes and hybridized
with specific probes.
Recent advances in PCR technology
have greatly increased our capability to
detect genetic polymorphisms of CYP
enzymes. With small amounts of human
tissue or cell samples, DNA amplification
can be carried out with proper PCR
primers for any particular sequence of a
polymorphic CYP gene. The DNA source
can be from blood leukocytes, buccal
epithelial cells, hair roots, or normally exfo-
liated cells, such as bladder epithelium in
the urine. DNA can also be obtained from
stored pathological tissue sections, which
provide great advantage for retrospective
studies. It is now feasible to determine sev-
eral CYP genetic polymorphisms with less
than 10 pl ofblood collected from the fin-
ger tip. The PCR-amplified DNA sequence
containing the polymorphic sites can then
be analyzed by RFLP with restriction diges-
tion and visualized on a stained gel after
electrophoresis. Comparing the wild-type
samples, if the genetic polymorphism
results in a loss-or in some cases a gain-
ofa restriction site, the band pattern on the
gel will be different. Ifthe PCR primers are
designed to be within the missing sequence
of a deletion polymorphism, there will be
no PCRproduct formed.
Obviously, the RFLP method cannot
be used to screen the CYP genetic poly-
morphisms in which the DNA sequence
alterations cause no changes at suitable
restriction sites. In this case, genotyping
can be carried out by allele-specific PCR
with a set of mutation-specific primers for
amplification. Several polymorphisms of
CYPlA], 2A6, and 2D6have been identi-
fied by the allele-specific PCR method
(18-20). If necessary, the results from
PCR-RFLP and allele-specific PCR can be
confirmed by PCR-direct sequencing.
In contrast to the phenotyping approach,
genotyping is not affected by drugs or
dietary factors that might modulate the
metabolic activity of CYP enzymes. As
mentioned previously, the PCR-based
genotyping techniques require only a small
amount ofDNA, which can be obtained by
less invasive or noninvasive means or from
longtime stored pathological samples. The
genotyping approach also allows accurate
prediction of the homozygous or heterozy-
gous status ofan individual who carries the
variant allele. All of these are particularly
useful for large population studies in which
genetic polymorphisms of CYP enzymes
may be susceptibility markers.
CYP Genetic Polymorphisms
and Cancer Risk
The association of CYP genetic polymor-
phisms and human cancer risk has received
increasing attention. Examples include
CYPIA] with lung and breast cancers
(21-23), CYP2D6with different types of
cancer (24), and CYP2EI with lung, liver,
and nasopharyngeal cancers (21,25-28).
However, many reports are controversial.
One important factor in interpreting these
results is that there are significant ethnic
differences in frequency distribution ofthe
CYP genetic polymorphisms. For example,
an association of CYP2E1 DraI genetic
polymorphism and susceptibility to lung
cancer was suggested in a study of a
Japanese population (29) but was not
observed in Caucasians (26,27,30). This
discrepancy was believed to be caused by a
significantly low distribution frequency of
CYP2E1 DraI polymorphism in Caucasian
populations (27).
Current Problems
and Perspectives
Research on genetic polymorphisms ofCYP
enzymes can provide a molecular basis for
interindividual variations in metabolizing
drugs and envirormental toxic chemicals.
In addition to this mechanistic information,
the studies hold great promise in identifying
susceptible individuals and protecting them
from environmental toxicity. If a given
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CYP polymorphic genotype causes enhance-
ment in the metabolic activation of the
related substrate toxicants, individuals with
such variant alleles should avoid exposure
to those toxic compounds. Knowing the
identity of the chemical to which one
would be exposed and the polymorphic
CYP form involved could be particularly
useful in preventing chemical toxicity from
occupational exposure. Studies on CYP
genetic polymorphism and environmental
toxicity could be very rewarding, and
research activities in this field are expected
to increase in the near future. However, we
are facing the following challenges:
a) With current PCR-based techniques
and rapid development of molecular biol-
ogy approaches, identification of CYP
genetic polymorphisms and genotypic
screening ofa subpopulation are not diffi-
cult. More new CYP genetic polymor-
phisms are expected to be discovered. The
most critical challenge, however, is to
establish the functional importance ofdif-
ferent polymorphic variants, especially for
those polymorphic sites located in the
noncoding regions of the CYP genes.
Using an in vitro transfection system with
CATas a reporter gene, it has been observed
that the RsaI polymorphic site in the
5'-flanking sequence of the CYP2E1 gene
caused a 10-fold increase in transcrip-
tional activity in comparison with the
wild-type sequence (31). It is important
to demonstrate whether such extent of
regulation occurs in vivo. Similarly, the
results from the in vitro activity assays
with the expressed variant CYP proteins
need to be verified in phenotypic studies
with human populations.
b) Our current efforts have been
focused on the association ofCYP genetic
polymorphisms with cancer risks and less
on the occupational toxicity in which the
biological end points are not cancer occur-
rence. Human carcinogenesis is a long-term,
multistep process. Although metabolic
activation by CYP enzymes is known to
constitute the first and critical step in envi-
ronmental carcinogens, there are many
other important steps involved, such as
phase II enzyme detoxification, DNA
repair, and immunosurveillance, as well as
many modulating factors such as dietary
components. In addition, it is difficult or
impossible to know the number and iden-
tityofthe carcinogens involved or the expo-
sure levels. Assessing the role of genetic
polymorphism ofa particular CYP form by
using cancer occurrence as a biological end
point is therefore a very difficult task. We
believe that at this stage it is more feasible
to determine the role ofCYP genetic poly-
morphisms in the susceptibility ofworkers
to chemical toxicity in occupational expo-
sures in which cancer occurrence is not an
end point. An advantage in using worker
populations is that the identity and the
exposure levels ofthe toxic chemicals are in
general clearly known. In addition, the
workers are probably more homogeneous
than the general population and more easily
accessible for follow-up studies.
c) More research is needed for charac-
terization of the substrate specificity and
the enzyme kinetics of human CYP
enzymes. Knowledge ofwhich environ-
mental toxicants and carcinogens are the
substrates ofthe polymorphic CYP enzymes
is important, but that knowledge is not
enough in designing a population study.
Although it is known that CYP enzymes
have overlapping substrate specificities, the
CYP form with a high Vma,, value and the
lowest Km value is usually the principal one
involved in the metabolism and is therefore
believed to be the one most relevant to the
situation in vivo. Obviously, if a particu-
lar CYP form is found to be able to acti-
vate a toxic chemical but the Km value is
much higher than the physiological con-
centration ofthat chemical after exposure,
that CYP form may be of little relevance
to the real in vivo situation. Studies in
this direction will also help in developing
more selective "probe" drugs for different
CYP forms, which is inevitably required
in establishing the relationship between
CYP genetic polymophisms and metabolic
activity in vivo.
d) More information is needed to
understand the regulation ofCYP enzymes
in humans. The studies should include the
effect ofdietary compounds on the expres-
sion of CYP enzymes and the expression
profile of CYP enzymes in the tissues that
are targets for chemical toxicity or carcino-
genesis. Without this information, the
role ofCYP genetic polymorphism in the
biological consequences may not be
accurately assessed.
e) Humans are exposed to numerous
environmental toxicants. For example,
more than 40 carcinogens have been found
in tobacco products and tobacco smoke
(32). Multiple polymorphic CYP enzymes
are involved in metabolizing these carcino-
gens. Even for a given subpopulation
mainly exposed to a single toxic chemical,
it is possible that more than one form of
CYP enzyme is involved in the activation
or detoxification. Therefore, it is recom-
mended that whenever possible a combina-
tional polymorphism analysis on all the
involved CYP forms be carried out to
obtain a complete picture of the role of
CYP enzymes in susceptibility to cancer
and toxicity. The availability of current
PCR technology allows us to use DNA
samples stored for extensive periods (e.g.,
blood dotted on filter paper or pathological
tissue sections) for the analysis ofdifferent
CYP genetic polymorphisms. In addition,
these DNA samples can be used for combi-
national genetic polymorphism analysis
with the phase II metabolizing enzymes
such as glutathione S-transferase and
N-acetyltransferase, or DNArepair enzymes.
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